Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harald Hampel

Showing results (1-10 of 411) with videos related to

Pageof 42
Sort By:
Journal of Alzheimer'S Disease : JAD|April 26, 2012
Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanismsHarald Hampel
International Psychogeriatrics|July 13, 2012
Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic interventionHarald Hampel
Progress in Neurobiology|December 6, 2011
Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's diseaseDavid Prvulovic, Harald Hampel
The Lancet. Neurology|September 25, 2003
CSF markers for incipient Alzheimer's diseaseKaj Blennow, Harald Hampel
Nature Reviews. Neurology|September 26, 2012
Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridgeHarald Hampel, Simone Lista
Alzheimer'S Research & Therapy|March 21, 2013
Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?Harald Hampel, Simone Lista
Expert Review of Neurotherapeutics|June 23, 2016
Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's diseaseSimone Lista, Harald Hampel
Dialogues in Clinical Neuroscience|October 29, 2011
CSF tau and β-amyloid as biomarkers for mild cognitive impairmentHarald Hampel, Kaj Blennow
Progress in Neurobiology|October 19, 2011
The role of genetics for biomarker development in neurodegenerationLars Bertram, Harald Hampel
Scandinavian Journal of Clinical and Laboratory Investigation|July 9, 2008
Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's diseaseHarald Hampel, Yong Shen
Pageof 42

Showing results (1-10 of 411) with videos related to

Sort By:
Pageof 42
Journal of Alzheimer'S Disease : JAD|April 26, 2012
Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanismsHarald Hampel
International Psychogeriatrics|July 13, 2012
Current insights into the pathophysiology of Alzheimer's disease: selecting targets for early therapeutic interventionHarald Hampel
Progress in Neurobiology|December 6, 2011
Ethical considerations of biomarker use in neurodegenerative diseases--a case study of Alzheimer's diseaseDavid Prvulovic, Harald Hampel
The Lancet. Neurology|September 25, 2003
CSF markers for incipient Alzheimer's diseaseKaj Blennow, Harald Hampel
Nature Reviews. Neurology|September 26, 2012
Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridgeHarald Hampel, Simone Lista
Alzheimer'S Research & Therapy|March 21, 2013
Have we learnt all we need to know from genetic studies - is genetics over in Alzheimer's disease?Harald Hampel, Simone Lista
Expert Review of Neurotherapeutics|June 23, 2016
Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's diseaseSimone Lista, Harald Hampel
Dialogues in Clinical Neuroscience|October 29, 2011
CSF tau and β-amyloid as biomarkers for mild cognitive impairmentHarald Hampel, Kaj Blennow
Progress in Neurobiology|October 19, 2011
The role of genetics for biomarker development in neurodegenerationLars Bertram, Harald Hampel
Scandinavian Journal of Clinical and Laboratory Investigation|July 9, 2008
Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's diseaseHarald Hampel, Yong Shen
Pageof 42